Skip to Content
Merck
  • The Fasciola hepatica tegumental antigen suppresses dendritic cell maturation and function.

The Fasciola hepatica tegumental antigen suppresses dendritic cell maturation and function.

Infection and immunity (2009-04-01)
Clare M Hamilton, David J Dowling, Christine E Loscher, Russell M Morphew, Peter M Brophy, Sandra M O'Neill
ABSTRACT

Parasitic worms and molecules derived from them have powerful anti-inflammatory properties and are shown to have therapeutic effects on inflammatory diseases. The helminth Fasciola hepatica has been reported to suppress antigen-specific Th1 responses in concurrent bacterial infections, thus demonstrating its anti-inflammatory ability in vivo. Here, F. hepatica tegumental antigen (Teg) was shown to significantly suppress serum levels of gamma interferon (IFN-gamma) and interleukin-12p70 (IL-12p70) in a model of septic shock. Since dendritic cells (DCs) are a good source of IL-12p70 and critical in driving adaptive immunity, we investigated the effects of F. hepatica Teg on the activation and function of murine DCs. While Teg alone did not induce cytokine production or cell surface marker expression on DCs, it significantly suppressed cytokine production (IL-12p70, IL-6, IL-10, tumor necrosis factor alpha, and nitrite) and cell surface marker expression (CD80, CD86, and CD40) in DCs matured with a range of Toll-like receptor (TLR) and non-TLR ligands. Teg works independently of the TLR4 pathway, since it still functioned in DCs generated from TLR4 mutant and knockout mice. It impaired DC function by inhibiting their phagocytic capacity and their ability to prime T cells. It does not appear to target the common components (extracellular signal-regulated kinase, Jun N-terminal protein kinase, or p38) of the TLR pathways; however, it suppressed the active p65 subunit of the transcription factor NF-kappaB in mature DCs, which could explain the impairment of proinflammatory cytokine production. Overall, our results demonstrate the potent anti-inflammatory properties of F. hepatica Teg and its therapeutic potential as an anti-inflammatory agent.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, Ready Made solution, 1 mg/mL
Sigma-Aldrich
SB 202190, ≥98% (HPLC)
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, FITC conjugate
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, Detoxified
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, purified by gel-filtration chromatography
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, purified by ion-exchange chromatography, TLR ligand tested
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, purified by trichloroacetic acid extraction
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, purified by phenol extraction
Sigma-Aldrich
Lipopolysaccharides from Escherichia coli O111:B4, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Immobilon®-P Polyvinylidene difluoride membranes, size 26.5 cm × 375 cm
Sigma-Aldrich
TRI Reagent®, for DNA, RNA and protein isolation
Sigma-Aldrich
TRI Reagent®, LS, For processing fluid samples such as cell suspensions, CSF, and amniotic fluid.
Sigma-Aldrich
TRI Reagent®, For processing tissues, cells cultured in monolayer or cell pellets
Sigma-Aldrich
TRI Reagent®, BD, For processing whole blood, plasma, or serum.